Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSAM4113 is a cannabinoid receptor 1 (CB1)-selective neutral antagonist that binds to CB1 and CB2 with Ki values of 0.89 and 92 nM, respectively.1 In rats, it has been shown to reduce food intake and food-reinforced behavior, such as time spent feeding, thereby reducing weight gain without inducing nausea.2 This compound has also been used to study the abuse-related effects of nicotine, as well as the effects of nicotine on anxiety and depressive-like behavior in rats.3
WARNING This product is not for human or veterinary use.
1. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-
2. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-
3. The CB1 neutral antagonist AM4113 retains the therapeutic efficacy of the inverse agonist rimonabant for nicotine dependence and weight loss with better psychiatric tolerability. Int. J. Neuropsychopharmacol. (2016).